Breaks Categories: News

MondayApr 24, 2017 9:58 am

NetworkNewsBreaks – Social Reality, Inc. (NASDAQ: SRAX) CEO Scheduled to Speak at the NAB Show

Internet advertising company Social Reality, Inc. (NASDAQ: SRAX) this morning announced that Christopher Miglino, its chairman and CEO, is scheduled to speak tomorrow at the NAB Show in Las Vegas. The NAB Show is the world’s largest convention encompassing the M.E.T. Effect, or the convergence of media, entertainment and technology. Miglino will be contributing to a panel titled “How Programmatic is Coming to TV” at 11:30 a.m. on April 25. The panel is part of the Fourth Annual Media Finance and Investor Program (MFIP), an official event at the NAB Show, and will be produced in partnership with Noble Capital…

Continue Reading

ThursdayApr 20, 2017 12:16 pm

NetworkNewsBreaks – Atossa Genetics, Inc.’s (NASDAQ: ATOS) Phase 1 Endoxifen Study Receives Positive Interim Review

Atossa Genetics (NASDAQ: ATOS) this morning said it has received a positive interim review on its phase 1 study of endoxifen, an active metabolite of the FDA-approved drug tamoxifen, indicated for breast cancer and breast cancer prevention in high risk patients. Upon reviewing the blinded data generated from the first cohort of the study of eight subjects, the Independent Safety Committee concluded that the study may advance to the next dosing level. "It is the first assessment of our clinical safety and tolerability data and it indicates that proceeding to the next dosing level with our proprietary topical Endoxifen is…

Continue Reading

ThursdayApr 20, 2017 9:45 am

NetworkNewsBreaks – MGX Minerals, Inc. (MGXMF) Announces Results from Independent Testing of Proprietary Lithium Extraction Process

Diversified mining company MGX Minerals, Inc. (OTC: MGXMF) this morning announced that it has received independent laboratory-testing results from the Saskatchewan Research Council (“SRC”) regarding its patent-pending “Method for Extraction of Lithium from Salt Brine” (U.S. Provisional Patent #62/419,011). The results from the SRC noted that MGX’s proprietary extraction process was successful in recovering up to 83.7% lithium and concentrating 461 ppm lithium from a 71 ppm representative sample of formation brine originating from the Sturgeon Lake oilfield. “The results of laboratory testing by SRC provide third-party validation of our proprietary design process and its ability to rapidly separate lithium…

Continue Reading

WednesdayApr 19, 2017 9:22 am

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Records Triple-Digit Revenue Growth in 2016

Emerging vertically integrated solid waste management company National Waste Management Holdings, Inc. (OTC: NWMH) this morning announced its financial results for the full year ended December 31, 2016. Among the highlights, the company’s revenues for the 12-month period totaled $6.3 million, marking a year-over-year increase of 161 percent. This strong revenue growth was fueled by NWMH’s aggressive acquisition-based growth strategy, which led to the acquisitions of both Northeast Data and Recycling, LLC and Sivart Services, LLC during the year ended December 31, 2016. “We executed a number of achievements throughout 2016, and are pleased to report the positive impacts of…

Continue Reading

TuesdayApr 18, 2017 12:21 pm

NetworkNewsBreaks – Biocept, Inc. (NASDAQ: BIOC) Expands IP with Japanese Patent for Target Selector™ Liquid Biopsy Platform

Biocept (NASDAQ: BIOC) this morning said it has been awarded a Japanese patent covering the use of antibodies for the capture of any target of interest from any sample type on a device surface including circulating tumor cells (CTCs). The patent, entitled “Devices And Methods Of Cell Capture And Analysis,” is broader than previously issued patents owned by the company and is the 19th patent issued to Biocept related to its core liquid biopsy technology. "This is our third patent issued in Japan, strengthening the protection of our proprietary liquid biopsy technology in an important healthcare market. Expanding our intellectual…

Continue Reading

TuesdayApr 18, 2017 12:18 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG): UnitedHealthcare Agrees to Cover ThyraMIR®; Shares Skyrocket

Interpace Diagnostics Group (NASDAQ: IDXG) shares are up 95% in late morning trade after the company said that UnitedHealthcare, the largest health plan in the United States, has agreed to cover its ThyraMIR® test used in assessing indeterminate thyroid nodule fine needle aspirate (FNA) biopsies. The coverage is now in effect and is subject to members' specific benefit plan design. Including the new coverage with UnitedHealthcare, Interpace's ThyGenX® and ThyraMIR assays are now covered for approximately 250 million patients nationwide. To view the full press release, visit: http://nnw.fm/CFDp7 About Interpace Diagnostics Group, Inc. Interpace is a fully integrated commercial company…

Continue Reading

MondayApr 17, 2017 2:48 pm

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Expands eXp Realty Management Team

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for the Agent-Owned Cloud Brokerage®, today announced the addition of four industry veterans to the management team of eXp Realty. The newly-appointed additions include Kee Wah Chung as Vice President of Agent Experience; Kathy Gordon as Vice President, Brokerage Operations; Scott Petronis as Chief Product and Technology Officer; and Mitch Robinson as Senior Vice President, Marketing and Communications. “Our daily objective is to be the most agent-centric brokerage firm in the world,” Russ Cofano, president and general counsel of eXp World Holdings, stated in the news release. “Adding Kee Wah, Kathy, Scott…

Continue Reading

MondayApr 17, 2017 11:55 am

NetworkNewsBreaks – OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) Fails To Meet Endpoints in Phase 2 Trial of Tarextumab; Discontinues Enrollment in Brontictuzumab Trial

OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) shares are down 19% after the company reported top-line results from the phase 2 PINNACLE clinical trial of tarextumab in previously untreated patients with extensive-stage small cell lung cancer. The combination of tarextumab plus chemotherapy results were undifferentiated from those of chemotherapy plus placebo, which means the trial did not meet its primary endpoint of progression-free survival or secondary endpoints of overall survival and biomarkers reflective of Notch pathway gene activation. Additionally, the company said it is discontinuing enrollment in the phase 1b clinical trial of brontictuzumab in combination with trifluridine/tipiracil in third-line colorectal cancer…

Continue Reading

MondayApr 17, 2017 11:38 am

NetworkNewsBreaks – Westport Fuel Systems (NASDAQ: WPRT) Signs Definitive Agreement to Sell its APU Assets for $70M; Shares Rally

Westport Fuel Systems (NASDAQ: WPRT) shares jumped 16% this morning after the company said it has entered into a definitive agreement to sell the assets of its Auxiliary Power Unit (APU) business for $70 million. The sale is consistent with the company’s strategy to streamline its business and focus on alternative fuel solutions for the transportation and automotive industries. The transaction is expected to close within a few weeks. "After a careful assessment of the APU product line and its fit with the other Westport Fuel Systems businesses, we decided it made the most sense for our shareholders to pursue…

Continue Reading

MondayApr 17, 2017 9:44 am

NetworkNewsBreaks – CytoDyn’s (CYDY) PRO 140 Not Granted Orphan Drug Designation Due to Broad HIV Treatment Potential

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that its application for Orphan Drug Designation for PRO 140 was not granted by the Office of Orphan Products Development of the U.S. Food and Drug Administration. Per the update, the company’s clinical stage monoclonal antibody was deemed to have potential to treat more than just the subset of multi-drug resistant HIV patients for which the designation was requested. CytoDyn is currently conducting multiple Phase 2b/3 trials of PRO 140, including one in combination with other antiretroviral agents in the patient population outlined in the company’s Orphan Drug Designation application, as…

Continue Reading